Imperial College London
Portrait Picture

DrChloeBloom

Faculty of Medicine, National Heart & Lung Institute

Clinical Senior Lecturer in Respiratory Epidemiology
 
 
 
//

Contact

 

chloe.bloom06

 
 
//

Location

 

Emmanuel Kaye BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cook:2021:10.1080/20016689.2021.1929757,
author = {Cook, J and Bloom, C and Lewis, J and Marjenberg, Z and Platz, JH and Langham, S},
doi = {10.1080/20016689.2021.1929757},
journal = {J Mark Access Health Policy},
pages = {1--10},
title = {Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease.},
url = {http://dx.doi.org/10.1080/20016689.2021.1929757},
volume = {9},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Evidence suggests that triple therapy for patients with chronic obstructive pulmonary disease (COPD) is being used in a broader range of patients than recommended by guidelines, which may have health and cost implications. Objective: To explore the relationship between national health technology assessment (HTA) agency appraisals and market penetration of two fixed-dose combination (FDC) triple therapies. Study design: HTAs from Q3 2017 to Q1 2020 from 10 countries were evaluated. Intervention: Glycopyrronium bromide/formoterol fumarate/beclomethasone (Trimbow®) and umeclidinium/vilanterol/fluticasone furoate (Trelegy™ Ellipta®). Main outcome measure: HTA restrictions and prescribing rates (days of therapy). Results: Seven countries (70%) imposed restrictions on use including prescription only for patients stable on free-combination triple therapy or not controlled on dual therapy, requirement of a specialist prescription or therapeutic plan, prescription only for patients with severe COPD, and use as second-line therapy or later. In general, countries that have imposed restrictions on the use of FDC triple therapies have seen a lower than average uptake. Conclusion: Payer guidance on prescribing FDC triple therapy may potentially support more appropriate prescribing in line with clinical guidelines. It is important for payers to consider which restrictions would ensure the most efficient use of scarce resources.
AU  - Cook,J
AU  - Bloom,C
AU  - Lewis,J
AU  - Marjenberg,Z
AU  - Platz,JH
AU  - Langham,S
DO  - 10.1080/20016689.2021.1929757
EP  - 10
PY  - 2021///
SN  - 2001-6689
SP  - 1
TI  - Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease.
T2  - J Mark Access Health Policy
UR  - http://dx.doi.org/10.1080/20016689.2021.1929757
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34122781
UR  - https://www.tandfonline.com/doi/full/10.1080/20016689.2021.1929757
UR  - http://hdl.handle.net/10044/1/90003
VL  - 9
ER  -
Download